XTX101, a tumor-activated CTLA-4
Xilio is leveraging its innovative platform to progress its checkpoint inhibitor program with XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 monoclonal antibody designed to deplete regulatory T cells when activated selectively (unmasked) in the tumor microenvironment (TME). The Phase 1 clinical trial is a first-in-human, multi-center, open-label trial designed to evaluate the safety and tolerability of XTX101
XTX101 Presentations & Publications
11/12/2021
XTX101 (CTLA-4) Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors
05/12/2021
XTX101 (CTLA-4) Poster Presentation at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 Virtual Symposium
Tumor-Activated Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Monotherapy and Anti-PD-1 Combination Benefit in Preclinical Models
11/13/2020
XTX101 (CTLA-4) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
Tumor-activated Fc-engineered Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Tumor-selective PD and Efficacy in Preclinical Models